Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
KAHI up 27% on nice volume! Thanks for the news MACH.
Good Morning all.
Sara : )
"I doubt you'll be getting the type of conjugal visits you want sir vinny."
Ah Mary... just because I don't give it away freely to everyone like you do (there's a good word for a female who does that) doesn't mean I don't like men. I also prefer not to associate with criminal types like you do with your recently paroled felon" friend Anthony.
But Vinny... she is right with the above statement, but not for the reason she is implying.
Sara
Thanks, we could use a little upswing.
Sara : )
Today's Candlestick
by: HojichaMan (41/M/Philadelphia, PA) 08/21/01 06:22 pm
Msg: 131004 of 131122
Earlier today, someone asked me to post a candlestick analysis, so . . .
Today's candlestick was a doji. Normally, that signals a reversal. It's the first true doji we've seen on this stock for 5 months. The last doji, about 5 months ago, was followed by about a 35% increase in price over the next 5 days. (Even a move of that magnitude would only get us back up to the .80's, so no big shakes).
Volume was low, so that mutes the reversal signal from the doji.
Western indicators all showing pretty oversold, so that provides a technical base for a reversal.
Conclusion: I'm looking for, but not sure of, a noticeable price upswing over the next 4-5 trading days. However, the price upswing may well peter out before reaching $1.
By the way, the last time I called an upswing, we went from .70 to $1.00 in 3 days -- by way of .62. So, judge this call after the full 4-5 days have elapsed, please.
Hoji
http://messages.yahoo.com/bbs?.mm=FN&action=m&board=4687979&tid=astn&sid=4687979&...
"It's the latest Technical Indicator, didn't you know?"
LOL... I must be behind the times. I now see why these guys do what they do... that's a pretty good pay check.
At least you nab these guys pretty fast.
Sara : )
Matt,
That's amazing... do you think he really gets that price for promos? That is so outrageous!
And who would believe this line?
Also observe that over the last few days prior to our promotion the price of the stock almost always rises as rumor of our involvement very often causes a phenomenon known as "Advance Volume King Activity."
Sara
p.s. I have a friend at work who runs his own website and is a real sharp programmer... I'll ask if he has any ideas for you.
BoP scores!
If I did not demolish anyone, then why did you feel the need to say I didn't?
Sara : )
Thank you for your efforts in attempting to clarify this issue. I completely agree with your analysis of the situation and applaud you for having more patience that I do.
There is no valid reason to make such a big issue about the eVWAP numbers being posted here. Means for verifying that information has been provided.
Have a great day!
Sara : )
Posted by: MMMARY In reply to: sarals who wrote msg# 4915 Date: 8/21/2001 3:30:57 PM (ET)Post # of 4917
I don't go to parking lots with......people like you. go and play there by yourself.
___________________________
Just say NO to stock fraud!
http://www.investorshub.com/boards/read_msg.asp?message_id=166429
Guess she can't refute what I said... no big surprise.
Sara
Response in Parking Lot. eom
"I can't post anything. They are using riduclous rules to try and keep the negative truths off the boards." - Mary
http://www.investorshub.com/boards/read_msg.asp?message_id=166364
Examples of posts by Mary left on the board:
http://www.investorshub.com/boards/read_msg.asp?message_id=163786
http://www.investorshub.com/boards/read_msg.asp?message_id=165554
http://www.investorshub.com/boards/read_msg.asp?message_id=165889 (includes a personal attack)
http://www.investorshub.com/boards/read_msg.asp?message_id=166262
As for negative posts being allowed, see above list.
Sara
Would you like to take this to the Parking Lot? It's where is belongs...
Sara
Rather than do your work for you, I will conclude that your statements were inaccurate, incomplete and misleading.
Sara
Provide the specific excerpt from the SEC document that talks about that and post a link to the entire document.
If you post the information and you want credibility, you must provide backup to that information when readily available, as in this case.
Sara
Maybe I was asleep at the wheel... lol. I'll rewind and relisten to that part of the tape. Ah yes, the name Buffet rings a bell... hee hee
Sara : )
On the 2nd tape of the audio and have found it very clear and concise... but a little on the dry side. I'm in danger of falling asleep at the wheel if I listen to it in the morning : )
So far the most interesting tid bit has been that you can buy Puts which are similar to short selling in that you are betting the stock price goes down, but loses are not unlimited like with shorting. Is that correct? It also made the statement that your maximum loss was the difference between striking price and book value. Is that true? Couldn't a stock fall below book value?
Sara : )
eVWAP 433,200 x 2
800-THE-PHLX, extension 5
Sara
EZ - I know that feeling about wishing for more cash : )
I'll keep my eyes open.
Have a great day!
Sara : )
Fortune's 100-Fastest Growing Companies
http://www.fortune.com/indexw.jhtml?channel=list.jhtml&list_frag=list_5column_fast_grow_companie...
"your the kind of person who starts a fight and then goes and tells the teacher about it like you did nothing"
You got it exactly!
Sara : )
eVWAP volumes can be verified by...
calling this number:
800-THE-PHLX, extension 5
This is being posted regularly for verification purposes.
Sara
p.s. any volumes over 1,000,000 can be verified at the ASTN website http://www.ashtontechgroup.com
Nice DD on DNAP... it sure had a nice day!
Sara : )
Thanks Muel. I discovered this little gem sometime back when it was featured in the local paper (local company). And I agree... this looks like a great entry point!
Sara : )
The point was showing you the reason I wanted you to backup your information, to make sure that it wasn't just based on hearsay... which you managed to do nicely.
It would save everyone a lot of time if you would provide the links to the backup for your information in your posts to start with.
Sara
Ashton trivia question
by: marycummins (35/F/Los Angeles, CA)
Long-Term Sentiment: Strong Sell 08/20/01 05:24 pm
Msg: 130749 of 130769
Someone emailed me this.
What is significant about today's closing price, besides all the numbers? .6498
I'll give you a few minutes. I actually didn't get it. They had to tell me. Hint, things are always worse than even I can imagine.
http://messages.yahoo.com/bbs?.mm=FN&action=m&board=4687979&tid=astn&sid=4687979&...
Little-Known Cancer Drug May Be the Surprise Hit of FDA Meeting
By Adam Feuerstein
Staff Reporter
8/20/01 9:27 AM ET
The next big event in biotech starts Sept. 11, when U.S. drug reviewers put a promising but controversial cancer drug from IDEC Pharmaceuticals (IDPH:Nasdaq - news - commentary - research) under the regulatory microscope.
But savvy investors looking to score might want to pay attention the day before to the Food and Drug Administration advisory panel meeting's opening act -- Matrix Pharmaceutical (MATX:Nasdaq - news - commentary - research).
The small, Fremont, Calif.-based biotech firm will go in front of the cancer drug advisory panel Sept. 10 seeking approval for IntraDose, a novel treatment used to help patients dying from head and neck cancer, the sixth-leading cause of cancer deaths in the U.S.
IntraDose has a very good shot at getting the thumbs-up from the FDA, based on the drug's efficacy and safety record, biotech observers say. And that should be good news for Matrix's stock, which is mostly ignored by investors and appears to be undervalued compared with many of its well-hyped rivals.
Matrix shares closed Friday at $8.97 per share, down almost 50% from their 52-week high in mid-January. The company sports a market value of just $234 million, puny compared with other biotech firms that have a single drug either approved or on the cusp of approval.
"Matrix's data [for IntraDose] is some of the most rock-solid stuff that I have ever seen," says one normally skeptical biotech hedge fund manager who has a significant long position in the stock.
Now, some caution is warranted. Like all biotech companies, there is a bear case to be made against Matrix and its chances at the FDA, and IntraDose will never be a blockbuster drug. But with estimated peak annual sales of about $100 million for IntraDose in the head and neck cancer market -- a figure that could grow substantially if the drug's use is expanded into other cancers -- Matrix is relatively low-risk.
What's so special about IntraDose? The treatment is not really a new drug at all, but a first-of-its-kind combination of three existing drugs into a cancer-fighting gel that is injected directly into solid tumors. Normally, chemotherapy drugs are injected intravenously and work their way through the blood stream to find and kill cancer cells. This long journey limits their effectiveness. But because IntraDose is injected directly into the tumor, it's more potent and works longer, or at least that's the theory.
IntraDose sounds so elegant and simple, so why is it the first injectable chemotherapy treatment used to treat tumors locally? The big hurdle is getting the cancer-fighting drug to actually stay inside the tumor. Matrix has apparently solved this problem by suspending the well-established chemotherapy drug Cisplatin inside a suspension of collagen gel, which forms a kind of goop that won't seep out of tumors. Added to this goop is epinephrine, which acts like a "chemical tourniquet" to clamp down on blood vessels around the tumor and further helps to keep the cancer-fighting drug inside.
Like many biotech firms developing cancer treatments, Matrix has tested IntraDose on the sickest of the sick first. It is seeking approval to market the drug for use in "refractory" head and neck cancer patients. Simply put, these are patients who have exhausted all other medical options and are weeks or months away from dying.
IntraDose is not a cure. Patients using the treatment still die and the company makes no claims about extending life. But 30% of patients in the company's late-stage test had their head and neck tumors either shrink significantly or disappear altogether, a significant amount for cancer research. Many of these tumors interfere with breathing or make swallowing difficult or impossible, so shrinking or destroying them makes patients much more comfortable.
"There is a growing realization that drugs are needed not just to cure disease but to improve the quality of life of patients with no options," says a doctor/analyst at another hedge fund with a long position in Matrix. "IntraDose will get approved because the drug shows a clear benefit for patients without putting them at any extra risk."
Stu Weisbrod, chief investment manager at the health care hedge fund Merlin Biomed Group, agrees. "IntraDose will get approved. It's a niche product, but the drug legitimizes Matrix's technology platform." Weisbrod is long Matrix.
If Matrix does run into problems at the FDA advisory panel meeting, it will be because of the unusual way IntraDose was tested. Instead of analyzing its data to measure the survival of patients taking the product, the company uses a subjective measure of patient benefit. In its two late-stage tests, IntraDose failed to meet preset patient benefit goals, although the combined data from the tests did pass.
FDA advisory panel meetings can be treacherous affairs because companies never know how independent reviewers will react to their data. Matrix bulls acknowledge that the company has some explaining to do, but the overall results should be strong enough for a positive recommendation.
Matrix is already testing IntraDose to expand its use -- and revenue-generating potential. It would like doctors to use the product in less critically ill head-and-neck cancer patients, as well as with patients suffering from advanced liver, colon and breast cancer. The thought here is that surgeons, for example, could use IntraDose to shrink tumors before going in to remove them. IntraDose might also be equally beneficial to patients receiving radiation therapy for solid-tumor cancers.
In this way, IntraDose could become part of a cancer cure, and not just a palliative treatment for terminally ill patients.
But even if Matrix gets approval for limited use of IntraDose, the company's $234 million market value seems like a screaming deal compared to its peers. By comparison, Ilex Oncology (ILXO:Nasdaq - news - commentary - research) shares sales of a single approved cancer drug, Campath, with two other companies but sports a market cap of $684 million.
And let's not even talk about Imclone (IMCL:Nasdaq - news - commentary - research) and its much-discussed experimental colon cancer drug, IMC-C225. This drug, not yet approved for use, seems to only marginally extend the lives of terminally ill patients, yet it's already pushed Imclone's market cap to a whopping $3.3 billion.
So as the Sept. 10-11 cancer drug advisory committee approaches, the hordes will be watching IDEC, but smart biotech investors should pay attention to the meeting's opening act. Matrix may just steal the show.
http://qw2001.quicken.com/investments/news/tst/notemplates/frame.dcg?symbol=MATX&ntlink=http://w...
post a link that shows those "closing low" figures.
52-week Range
0.6100 - 4.2500
http://finance.yahoo.com/q?s=ASTN&d=t
"totally devoid of relevance."
probably... he doesn't seem to want to try and explain it.
Have a great day!
Sara : )
eVWAP 2,259,100 x 2
800-THE-PHLX, extension 5
Now now... don't go spreading false rumors about me.
Congrats guys.
Sara : )
So what was your post about?
"perl -e "print(pack('h32','74f602645736b60295f657273756c666'));"
Sara
light matches? hee hee
Looking good!
I have a question though... did you change the font when viewing the message board list so that the title/first line of text is a different font than the name of the poster? was it the same before... it looks different somehow.
You're really on a roll!
Sara : )
Alternative trading systems get green light
http://www.thestar.com/NASApp/cs/ContentServer?pagename=thestar/Layout/Article_Type1&c=Article&a...
Whoa! You've got to check this out... looks like she's just getting herself in more and more trouble!
"Special thread to detail a case of slander on RB. . ."
http://www.investortoinvestor.com/dcforum/NewsletterDiscussion/68.html
Won't it be a trip; if all the evidence from Puke-r-ific's hearings (..and those for subsequent known cohorts..), which become part of the public record - show up as exhibits for ASTN in Philadelphia...!!
I was thinking the same thing... there's still room for some John Does!
Sara
More...
notice ASTN on the list...
To:TheTruthseeker who wrote (2911)
From: sommovigo Wednesday, Dec 27, 2000 11:44 PM
Respond to of 3128
Floyd - why did your extremely close friend and investing partner, Auric Goldfinger,
have an 87,600 share long position in CYBR for his Barbary Coast Capital
Management Hedge Fund? Why on EARTH would Auric "Barbary Coast Capital Management"
Wolverine-Tongue OWN $871,894 worth of CYBR shares?
After all of his BASHING of the company on these boards, you would think that he
would never buy such a HUGE position in the stock... it is an inconsistency that has
not been overlooked or unreported.
I wonder what your trading records, or those of Elgindy, Pluvia, Mr. Pink, and the
numerous lemmings in the Posse would reveal? Do you think that the SEC would be interested?
http://www.secinfo.com/$/SEC/Filing.asp?T=svrb.52Y3_lv
Barbary Coast Capital · 13F-HR · For 6/30/0, As Of 11/2/0
Table in Document 1 of 1 · 13F-HR · Quarterly Holdings or Combination Report by an Institutional Money Manager
Download this table in: Spreadsheet Format (.csv)
--------------------------------------------------------------------------------
REPORTING MANAGER: Furman Selz LLC
VALUATION CURRENCY: USD
ITEM 6 ITEM 7
ITEM 2 ITEM 4 ITEM 5 VEST. DISC. MANA-
TITLE ITEM 3 FAIR SHARES OF IN SHARED GERS
ITEM 1 OF CUSIP MARKET PRINCIPAL SOLE SHARED OTHER SOLE
NAME OF ISSUER CLASS NUMBER VALUE AMOUNT (A) (B) (C) (A)
-------------------------- ------- ----------- ------------ ------- ---- ------------ --------
ACTEL CORP OTC EQ 4934105 848,625 18,600 N X BARB 18,600
ADAM SOFTWARE INC OTC EQ 00547M101 80,000 20,000 N X BARB 20,000
ADVANCE PARADIGM INC OTC EQ 7491103 455,100 22,200 N X BARB 22,200
AMES DEPARTMENT STORES INC OTC EQ 30789507 383,625 49,500 N X BARB 49,500
ARQULE INC OTC EQ 4269E107 484,375 25,000 N X BARB 25,000
ASHTON TECHNOLOGIES GROUP OTC EQ 45084100 228,922 80,500 N X BARB 80,500
AMERICAN XTAL TECHNOLOGY OTC EQ 30514103 912,575 21,100 N X BARB 21,100
BARRA INC OTC EQ 68313105 2,344,306 47,300 N X BARB 47,300
BLACK BOX CORP-DEL OTC EQ 91826107 1,520,100 19,200 N X BARB 19,200
BEST BUY COMPANY INC COMMON 86516101 683,100 10,800 N X BARB 10,800
C R BARD INC COMMON 67383109 770,000 16,000 N X BARB 16,000
BILLSERV.COM INC OTC EQ 90181108 229,687 25,000 N X BARB 25,000
BITWISE DESIGNS INC OTC EQ 91747105 519,937 88,500 N X BARB 88,500
CALIFORNIA MICRO DEVICES CORP OTC EQ 130439102 1,366,875 45,000 N X BARB 45,000
COMPLETE BUSINESS SOLUTION OTC EQ 20452F107 1,088,875 62,000 N X BARB 62,000
CDW COMPUTER CENTERS INC OTC EQ 125129106 2,137,500 34,200 N X BARB 34,200
CREATIVE HOST SERVICES INC OTC EQ 22527P102 471,625 38,500 N X BARB 38,500
CIENA CORP OTC EQ 171779101 1,533,525 9,200 N X BARB 9,200
***CORE LABORATORIES NV COMMON N22717107 609,000 21,000 N X BARB 21,000
COMPUTER LEARNING CENTER INC OTC EQ 205199102 71,575 81,800 N X BARB 81,800
CHOICEPOINT INC COMMON 170388102 1,152,550 25,900 N X BARB 25,900
CRAY INC OTC EQ 225223106 147,125 42,800 N X BARB 42,800
CREE INC OTC EQ 225447101 627,450 4,700 N X BARB 4,700
1-800 CONTACTS INC OTC EQ 681977104 752,000 16,000 N X BARB 16,000
CATALYTICA INC OTC EQ 148885106 1,362,350 123,850 N X BARB 123,850
CITRON INC OTC EQ 177383106 400 20,000 N X BARB 20,000
CYBER CARE INC OTC EQ 23243T105 871,894 87,600 N X BARB 87,600
[remainder of table snipped]
http://www.siliconinvestor.com/stocktalk/msg.gsp?msgid=15089785
There's quite a scoop going on over on Yahoo ASTN board... have no idea how much truth there is to it... but it looks like another one of Ms. Muffet's buddies could have been bashing stocks and not disclosing his professional status. Isn't that a big no no? Isn't that the same kind of thing she is so up in arms about Westergard about? Why would she apply two standards for the same behavior?
What's that saying about the company you keep?
Look what Google turned up
by: reverb101 08/17/01 05:37 pm
Msg: 130440 of 130454
http://www.siliconinvestor.com/stocktalk/msg.gsp?msgid=15092241
Looks like it isn't the first time Auric bashes a stock while his hedge fund holds a long position. Interesting theory here about why it smells funny. Look at the posts before it too.
This gets more and more interesting all the time.
http://messages.yahoo.com/bbs?.mm=FN&action=m&board=4687979&tid=astn&sid=4687979&...
To:TheTruthseeker who wrote (2921)
From: sommovigo Thursday, Dec 28, 2000 1:12 PM
View Replies (1) / Respond to of 3128
Floyd - also, regarding your assumption that it was a buy to cover a short: Would suspect then, if you are correct, that we have ample evidence to suggest the possibility that Auric - professional broker/dealer - stood to financially benefit by his chronic message board bashing of CYBR and that MAY POSSIBLY be construed as an attempt at manipulation, since every electronic communication with the public that a broker/dealer makes is considered, by law, to be a PROFESSIONAL ADVERTISEMENT and subject to regulation.
If trading records of the "Elgindy Clan' were to be subpoenaed and inspected, they MIGHT POSSIBLY reveal a similar trading pattern surrounding CYBR for many if not all of the members of Elgindy's private service. Should that prove to be the case, it MIGHT be argued that Auric WolverineTongue quite POSSIBLY used the wealth of the members of that board to leverage hisown hedge-fund short sale if they acted in unison at the recommendation of Auric OR Elgindy.
In any event, Auric's actions on these boards regarding CYBR along with his professional status and his trading records for Barbary Coast Capital Management create enough suspicion to warrant a possible SEC investigation into the matter.
http://www.siliconinvestor.com/stocktalk/msg.gsp?msgid=15092241
LOL... can't blame me for hoping for a minute!
Sara : )